Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 60/100

Placement of Entitlement Offer Shortfall

Wednesday, January 24, 2024 1 min read
Key Takeaway: Radiopharm Theranostics has announced the placement of entitlement offer shortfall. This comes alongside positive clinical updates and the initiation of a Phase 1/2a clinical study for BetaBart (RV-01). The company has also received IND approval from the US FDA to begin a therapeutic study targeting B7H3.

Market Sentiment Analysis

POSITIVE FACTORS

  • Radiopharm Theranostics has received IND approval from the US FDA.
  • The company is advancing its clinical studies with positive updates across four programs.

Full Press Release Details

• Announcements
• Price Sensitive
• January 24, 2024
Loading Viewer…

More Announcements & Updates

• Announcements
• September 28, 2023
• Analyst Reports
• May 13, 2025
• Announcements
• October 26, 2022
• Updates
• January 24, 2025

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What is the recent announcement by Radiopharm Theranostics?

Radiopharm Theranostics announced the placement of entitlement offer shortfall.

What clinical study is Radiopharm initiating?

Radiopharm is initiating a Phase 1/2a clinical study for BetaBart (RV-01).

What approval did Radiopharm receive from the FDA?

The company received IND approval from the US FDA to begin a therapeutic study targeting B7H3.

What updates has Radiopharm provided?

Radiopharm has provided positive updates across four clinical programs.

Tags: RADX Viatris Investor Conferences Healthcare FDA approval BetaBart clinical study radiopharmaceuticals
Last updated: Jan 24, 2024